QNRX vs. DYNT, TNON, NMRD, RSLS, GMVDF, IONM, OSAP, OSA, AEMD, and BJDX
Should you be buying Quoin Pharmaceuticals stock or one of its competitors? The main competitors of Quoin Pharmaceuticals include Dynatronics (DYNT), Tenon Medical (TNON), Nemaura Medical (NMRD), ReShape Lifesciences (RSLS), G Medical Innovations (GMVDF), Assure (IONM), ProSomnus (OSAP), ProSomnus (OSA), Aethlon Medical (AEMD), and Bluejay Diagnostics (BJDX). These companies are all part of the "surgical & medical instruments" industry.
Dynatronics (NASDAQ:DYNT) and Quoin Pharmaceuticals (NASDAQ:QNRX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, media sentiment, profitability, institutional ownership, valuation, community ranking, earnings, analyst recommendations and dividends.
Quoin Pharmaceuticals has a net margin of 0.00% compared to Quoin Pharmaceuticals' net margin of -14.13%. Quoin Pharmaceuticals' return on equity of -54.88% beat Dynatronics' return on equity.
Dynatronics has higher revenue and earnings than Quoin Pharmaceuticals. Dynatronics is trading at a lower price-to-earnings ratio than Quoin Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Dynatronics received 304 more outperform votes than Quoin Pharmaceuticals when rated by MarketBeat users. However, 55.56% of users gave Quoin Pharmaceuticals an outperform vote while only 50.91% of users gave Dynatronics an outperform vote.
4.2% of Dynatronics shares are owned by institutional investors. Comparatively, 8.6% of Quoin Pharmaceuticals shares are owned by institutional investors. 9.1% of Dynatronics shares are owned by insiders. Comparatively, 3.3% of Quoin Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Dynatronics currently has a consensus price target of $3.80, suggesting a potential upside of 717.20%. Quoin Pharmaceuticals has a consensus price target of $4.00, suggesting a potential upside of 419.41%. Given Quoin Pharmaceuticals' higher probable upside, analysts plainly believe Dynatronics is more favorable than Quoin Pharmaceuticals.
Dynatronics has a beta of 0.41, suggesting that its share price is 59% less volatile than the S&P 500. Comparatively, Quoin Pharmaceuticals has a beta of 1.85, suggesting that its share price is 85% more volatile than the S&P 500.
In the previous week, Quoin Pharmaceuticals had 3 more articles in the media than Dynatronics. MarketBeat recorded 5 mentions for Quoin Pharmaceuticals and 2 mentions for Dynatronics. Quoin Pharmaceuticals' average media sentiment score of 0.00 equaled Dynatronics'average media sentiment score.
Summary
Dynatronics and Quoin Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.
Get Quoin Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for QNRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding QNRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Quoin Pharmaceuticals Competitors List
Related Companies and Tools
